Functional impact of CYP2C5, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans

被引：72

作者：

Allabi, AC

Gala, JL

Horsmans, Y

Babaoglu, MO

Bozkurt, A

Heusterspreute, M

Yasar, U

机构：

[1] Catholic Univ Louvain, St Luc Univ Hosp, Ctr Human Genet, B-1200 Brussels, Belgium

[2] Catholic Univ Louvain, St Luc Univ Hosp, Clin Pharmacol Unit, B-1200 Brussels, Belgium

[3] Hacettepe Univ, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 76卷 / 02期

关键词：

D O I：

10.1016/j.clpt.2004.04.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background and Aim: Previous data indicate that the urinary losartan/E-3174 ratio is a marker for cytochrome P450 (CYP) 2C9 activity in vivo. The functional impact of CYP2C9(star)5, (star)6, (star)8, and (star)11 polymorphisms in vivo has not been investigated previously in humans. Methods: A single oral dose of losartan (25 mg) was given to 19 Beninese subjects with CYP2C9(star)1/(star)1 (n = 9), (star)1/(star)5 (n = 1), (star)1/(star)6 (n = 1), (star)1/(star)8 (n = 2), (star)1/(star)11 (n = 3), (star)5/(star)6 (n = 1), (star)5/(star)8 (n = 1), and (star)8/(star)11 (n = 1) genotypes. Concentrations of losartan and its active metabolite E-3174 were determined in urine from 0 to 8 hours by HPLC. The losartan/E-3174 metabolic ratio was used as a measure of losartan oxidation in vivo. Results: The urinary losartan/E-3174 ratio in the various genotypes was as follows: 1.85 +/- 2.4 (mean +/- SD) for CYP2C9(star)1/(star)1, 14.6 for CYP2C9(star)1/star5, 4.2 for CYP2C9(star)1/(star)6, 188 for CYP2C9(star)5/(star)6, 11.6 for CYP2C9(star)5/(star)8, 0.44 +/- 0.13 (mean +/- SD) for CYP2C9(star)1/(star)8, 2.2 for CYP2C9(star)8/(star)11, and 5.72 +/- 4.5 (mean +/- SD) for CYP2C9(star)1/(star)11. Compared with the CYP2C9(star)1/(star)1 genotypes, the losartan/E-3174 ratio was significantly different in the CYP2C9(star)5 allele carriers (CYP2C9(star)1/(star)5, CYP2C9(star)5/(star)8, and CYP2C9(star)5/(star)6 genotypes) (P = .01, Mann-Whitney) but was not different in CYP2C9(star)1/(star)8 (P = .16) and CYP2C9(star)1/(star)11 (P = .11) carriers. The urinary losartan/E-3174 ratio of the single CYP2C9(star)1/(star)6 subject was higher than the 95% confidence interval of the mean of the CYP2C9(star)1/(star)1 group (0.0-3.7), whereas the metabolic ratio of the CYP2C9(star)8/(star)11 carrier was inside the 95% confidence interval of the means of the CYP2C9(star)1/(star)1 and CYP2C9(star)1/(star)11 groups (0.0-18). Conclusions: The CYP2C9(star)5 and (star)6 alleles are associated with decreased enzyme activity in vivo compared with the wild-type variant, whereas the CYP2C9(star)8 and (star)11 variants did not appear to have large in vivo effects.

引用

页码：113 / 118

页数：6

共 30 条

[21] Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
Scordo, MG
Aklillu, E
Yasar, U
Dahl, ML
Spina, E
Ingelman-Sundberg, M
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 447 - 450
[22] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
Sekino, K
Kubota, T
Okada, Y
Yamada, Y
Yamamoto, K
Horiuchi, R
Kimura, K
Iga, T
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 589 - 592
[23] Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene:: In vitro and in vivo studies
Shintani, M
Ieiri, I
Inoue, K
Mamiya, K
Ninomiya, H
Tashiro, N
Higuchi, S
Otsubo, K
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 175 - 182
[24] Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
Takahashi, H
Wilkinson, GR
Caraco, Y
Muszkat, M
Kim, RB
Kashima, T
Kimura, S
Echizen, H
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) : 253 - 263
[25] Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype
Uchida, S
Watanabe, H
Nishio, S
Hashimoto, H
Yamazaki, K
Hayashi, H
Ohashi, K
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) : 505 - 508
[26] VALIDATION OF THE TOLBUTAMIDE METABOLIC RATIO FOR POPULATION SCREENING WITH USE OF SULFAPHENAZOLE TO PRODUCE MODEL PHENOTYPIC POOR METABOLIZERS
VERONESE, ME
MINERS, JO
RANDLES, D
GREGOV, D
BIRKETT, DJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (03) : 403 - 411
[27] Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations
Yasar, Ü
Aklillu, E
Canaparo, R
Sandberg, M
Sayi, J
Roh, HK
Wennerholm, A
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (08) : 555 - 558
[28] Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
Yasar, Ü
Dahl, ML
Christensen, M
Eliasson, E
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (02) : 183 - 185
[29] Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype
Yasar, Ü
Forslund-Bergengren, C
Tybring, G
Dorado, P
Llerena, A
Sjöqvist, F
Eliasson, E
Dahl, ML
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) : 89 - 98
[30] Yasar Ü, 2001, DRUG METAB DISPOS, V29, P1051

← 1 2 3 →

Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans

Functional impact of CYP2C5, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans